# CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia

> **NCT07464951** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Stephan Grupp MD PhD** · enrollment: 30 (estimated)

## Conditions studied

- Acute Myeloid Leukemia (AML)

## Interventions

- **BIOLOGICAL:** Anti-CD123 LV redirected T cells (CART123)
- **DRUG:** Ruxolitinib (JAKAVI®)

## Key facts

- **NCT ID:** NCT07464951
- **Lead sponsor:** Stephan Grupp MD PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-01
- **Primary completion:** 2029-04-30
- **Final completion:** 2030-04-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-03-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07464951

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07464951, "CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07464951. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*